PacBio reported fourth-quarter 2025 revenue of $44.6 million, up 14% year over year and 16% sequentially, bringing full-year revenue to $160 million. Consumables hit an all-time quarterly high at $21.6 million and $82 million for the year, while non-GAAP gross margin improved to 40% in both Q4 and full year. Non-GAAP operating expenses fell to $229.9 million from $289.2 million in 2024, narrowing the non-GAAP net loss to $158.8 million. The company exited 2025 with $279.5 million in cash and investments after completing the sale of its short-read assets for approximately $48.1 million, and flagged an upcoming 2026 launch of SPRQ-NX intended to significantly reduce sequencing costs.
The headline is not just a beat on revenue or margins; it is a strategic consolidation around long-read sequencing and an explicit attempt to solve the cost barrier that has kept long-read largely in research and specialty use. PacBio’s revenue mix shift toward consumables, steady system pull-through near $240,000 per Revio annually, and slower instrument placements suggest an installed base that is working harder rather than expanding rapidly. That profile, combined with tightened operating spend and divestiture of short-read assets, points to a company betting that clinical and translational demand for structural variant–rich, phasing-aware data is close to tipping—if price points move.
For pharma leaders, this matters on three fronts. First, rare disease discovery and natural history work are increasingly long-read–enabled, evidenced by PacBio’s integration into the iHope network and adoption of HiFi as a first-line approach in investigations of sudden unexplained death in childhood. Lower per-sample costs could shift long-read from a confirmatory tool to an earlier-line modality in rare disease cohorts, accelerating variant resolution, shortening diagnostic odysseys, and enriching patient-finding funnels for gene therapy and RNA-targeting programs. Second, the collaborations with n-Lorem and EspeRare underscore a pathway where long-read informs n-of-1 and ultra-rare development, sharpening target validation, allele phasing, and off-target assessment—areas where Medical Affairs can drive real-world evidence and payer-relevant utility beyond case reports. Third, multiomic advances such as the CiFi long-read 3C method open avenues for chromatin structure and structural variant interplay in oncology and neurology, with biomarker and companion strategy implications that commercial teams will need to map against coverage landscapes.
Payers and health systems will watch whether SPRQ-NX can reset the total cost of ownership for long-read workflows in high-yield indications. If consumables pricing and throughput reach thresholds compatible with existing reimbursement for exome or short-read whole genome testing, coverage policies could evolve toward broader adoption, especially where structural variants, repeat expansions, and phasing change clinical decisions. Turnaround times, informatics burden, and reportable finding rates will be as pivotal as sticker price; Medical Affairs will need to generate prospective, indication-specific utility data and economic models to move guidelines and payer policies.
Competitive dynamics are tightening. Oxford Nanopore continues to push portability and adaptive sampling, while short-read incumbents bolster long-read capabilities through chemistry and assembly approaches. PacBio’s decision to exit short-read simplifies its story but concentrates execution risk around clinical translation, cost deflation, and evidence generation. The improved margins and record consumables are green shoots, yet balance sheet vigilance remains prudent for partners planning long-horizon studies or CDx programs.
The strategic question for 2026 is whether PacBio’s SPRQ-NX can catalyze a durable shift from research-centric long-read to first- or early-line use in defined clinical pathways. If cost, throughput, and evidence align, pharma could unlock faster patient identification, richer genomic endpoints, and more precise safety analytics across rare disease and cell and gene therapy portfolios. If not, entrenched short-read economics and capital constraints may keep long-read growth confined to islands of excellence rather than a market-wide tide.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
